摘要
目的探究RNF168在乳腺癌组织中的表达情况及其临床价值。方法收集2013年1月‐2016年1月南方医科大学附属顺德医院319例乳腺癌患者的临床资料并进行随访,根据TNM国际标准,将319例患者分为I、II、III及IV4个级别。通过免疫组化的方法确定RNF168在癌细胞中表达的阳性率从而区分RNF168在癌组织中属于高表达或低表达。通过SPSS 16.0软件进行t检验。结果 RNF168在癌组织中表达显著高于正常组织,并且随着乳腺癌的发展,RNF168表达显著升高。结论 RNF168或许可以作为判断乳腺癌发生发展的一个重要指标,或许可以作为治疗乳腺癌的一个新靶点。
【Objective】To investigate the expression of RNF168 in breast cancer tissue and its clinical value.【Methods】Clinical data of 319 breast cancer patients in Shunde Hospital Affiliated to Southern Medical University from January 2013 to January 2016 were collected and followed up. According to TNM international standard, 319 cases were divided into four grades: I, II, III and IV. The positive rate of RNF168 expression in cancer cells was determined by immunohistochemical method, so as to distinguish RNF168 from high or low expression in cancer tissues. T-test was carried out by SPSS 16.0 software.【Results】The expression of RNF168 in cancer tissues was significantly higher than that in normal tissues, and with the development of breast cancer, the expression of RNF168 increased significantly. 【Conclusion】RNF168 may be an important indicator of the occurrence and development of breast cancer, and may be a new target for the treatment of breast cancer.
作者
罗小丽
刘自光
何慧君
吴国标
LUO Xiaoli;LIU Ziguang;HE Huijun;WU Guobiao(Department of Pathology,Shunde Hospital Affiliated to Southern Medical University,Shunde,Guangdong 528300,China;Department of Breast and Thyroid Surgery,Shunde Hospital Affiliated to Southern Medical University,Shunde,Guangdong 528300,China)
出处
《中国医学工程》
2019年第2期6-9,共4页
China Medical Engineering
基金
佛山市卫生和计生局医学科研课题(20170293)
